BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24405857)

  • 1. An update on molecular biology of thyroid cancers.
    Omur O; Baran Y
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma.
    Sethi K; Sarkar S; Das S; Rajput S; Mazumder A; Roy B; Patra S; Mohanty B; El-Naggar AK; Mandal M
    J Exp Ther Oncol; 2011; 9(3):187-99. PubMed ID: 22070050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathology of differentiated thyroid cancer.
    Greco A; Borrello MG; Miranda C; Degl'Innocenti D; Pierotti MA
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):440-53. PubMed ID: 19910897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic markers and prognostic factors in thyroid cancer.
    Vriens MR; Schreinemakers JM; Suh I; Guerrero MA; Clark OH
    Future Oncol; 2009 Oct; 5(8):1283-93. PubMed ID: 19852742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.
    Nikiforova MN; Nikiforov YE
    Expert Rev Mol Diagn; 2008 Jan; 8(1):83-95. PubMed ID: 18088233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy.
    Yip L
    J Surg Oncol; 2015 Jan; 111(1):43-50. PubMed ID: 25155423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
    Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
    J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic implications from molecular testing of thyroid cancer.
    Ozgursoy OB; Eisele DW; Tufano RP
    Otolaryngol Clin North Am; 2014 Aug; 47(4):595-607. PubMed ID: 25041960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in the clinical application of thyroid cancer biomarkers.
    Shibru D; Chung KW; Kebebew E
    Curr Opin Oncol; 2008 Jan; 20(1):13-8. PubMed ID: 18043251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling pathways in follicular cell-derived thyroid carcinomas (review).
    Romitti M; Ceolin L; Siqueira DR; Ferreira CV; Wajner SM; Maia AL
    Int J Oncol; 2013 Jan; 42(1):19-28. PubMed ID: 23128507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual thyroid tumors: a review of pathologic and molecular diagnosis.
    Hunt JL
    Expert Rev Mol Diagn; 2005 Sep; 5(5):725-34. PubMed ID: 16149875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside.
    Abdel-Rahman O
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):45-54. PubMed ID: 25560732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of NF-kappaB in thyroid cancer.
    Pacifico F; Leonardi A
    Mol Cell Endocrinol; 2010 May; 321(1):29-35. PubMed ID: 19879919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights in Thyroid Cancer and p53 Family Proteins.
    Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thyroid tumors--moleculargenetic causes and choices for target therapy].
    Bela B; Sárka D; Vlasta S; Eliska V; Tereza H
    Cas Lek Cesk; 2012; 151(3):123-7. PubMed ID: 22679698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.